Advancing Treatment in Primary Biliary Cholangitis (PBC): Insights Into a Selective PPARδ Agonist

Description

Join us for a product theater on an FDA-approved treatment option for primary biliary cholangitis (PBC). Gain insights into how this therapy may support improved PBC outcomes for the appropriate patients affected by this chronic liver disease.

Industry Supporter: Gilead Sciences